RxDoctor Payments Data

Jasmina Dukovic, PA

Physician Assistant · Downey, CANPI 1457021677

Payments from drug & device makers

$6,854in general payments, 2019–2025

Across 233 payments — averaging $29.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$1K
  • Sumitomo Pharma America, Inc.$861
  • Dendreon Pharmaceuticals LLC$562
  • Astellas Pharma US Inc$486
  • Bayer$368
  • Axonics, Inc.$345
  • plus $3K from 27 others

What the payments were for

  • Travel & lodging$3375%
  • Food & beverage$6,04788%
  • Education$4717%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,854 in reported general payments places this provider in the 95th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$48,553
Medicare patients
190
Services billed
6,590

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrgovyxRelugolix108$277,851
MyrbetriqMirabegron238$218,486
GemtesaVibegron203$206,380
Abiraterone Acetate18$35,740
PremarinEstrogens, Conjugated49$20,915
Solifenacin Succinate221$15,507
Trospium Chloride ErTrospium Chloride51$13,476
Mirabegron ErMirabegron12$7,606
Tamsulosin Hcl464$6,614
Estradiol106$5,982
Oxybutynin Chloride ErOxybutynin Chloride182$5,622
Methenamine Hippurate33$3,946
Finasteride230$2,816
Tolterodine Tartrate ErTolterodine Tartrate24$2,418
Potassium Citrate ErPotassium Citrate13$2,135

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$861$484,230311 claims
Astellas Pharma US IncMyrbetriq$486$218,486238 claims
PfizerPremarin$155$20,91549 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Downey

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →